UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net income	$ 10,798	$ 14,727	$ 18,555
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	655	700	765
Amortization	6,515	6,144	2,191
Gain on investments	0	0	(32)
Provision for losses on accounts receivable	(5)	14	20
Amortization of Right of Use Assets	39	38	0
Loss/(Gain) on disposal of assets	1	16	(410)
Deferred income taxes	(26)	(396)	(326)
Stock-based compensation expense	160	113	64
Tax benefit attributable to exercise of stock options	7	23	49
Accounts receivable	617	(738)	(496)
Other receivables	45	(16)	0
Inventories	924	(1,686)	(244)
Prepaid expenses and other current assets	108	(16)	(68)
Accounts payable	(308)	114	52
Accrued expenses	607	(1,651)	(558)
Long-term repatriation tax payable	0	(330)	(2,728)
Net cash provided by operating activities	20,137	17,056	16,834
Cash flows from investing activities:
Property and equipment	(860)	(540)	(402)
Intangible assets	0	(21,000)	0
Proceeds from the sale of investments	0	0	74
Proceeds from the sale of property and equipment	0	0	862
Net cash provided by (used in) investing activities	(860)	(21,540)	534
Cash flows from financing activities:
Proceeds from issuance of common stock - options	358	283	454
Common stock purchased and retired	(6,976)	(398)	(1,205)
Dividends paid	(4,116)	(4,112)	(4,026)
Net cash (used in) financing activities	(10,734)	(4,227)	(4,777)
Effect of exchange rate changes on cash	260	386	(1,354)
Net increase (decrease) in cash and cash equivalents	8,803	(8,325)	11,237
Cash at beginning of year	42,787	51,112	39,875
Cash at end of year	51,590	42,787	51,112
Cash paid during the period for income taxes	3,186	5,304	4,851
Cash paid during the period for interest	$ 0	$ 0	$ 0